CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Kontrakty CFD to złożone instrumenty, które wiążą się z dużym ryzykiem gwałtownej straty środków na skutek zastosowania dźwigni finansowej. 70% inwestorów detalicznych odnotowuje straty w handlu kontraktami CFD z tym dostawcą. Powinieneś rozważyć, czy rozumiesz, jak działają kontrakty CFD i czy możesz sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy. Prosimy o zapoznanie się z naszym Oświadczeniem o ryzyku
Oceny i recenzje
Oceny i recenzje
